151 related articles for article (PubMed ID: 38291158)
21. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
[TBL] [Abstract][Full Text] [Related]
22. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
Huang JT; Zhong BY; Jiang N; Li WC; Zhang S; Yin Y; Yang J; Shen J; Wang WS; Zhu XL
J Hepatocell Carcinoma; 2022; 9():1217-1228. PubMed ID: 36474670
[TBL] [Abstract][Full Text] [Related]
23. Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study.
Cao F; Shi C; Zhang G; Luo J; Zheng J; Hao W
BMC Cancer; 2023 Sep; 23(1):873. PubMed ID: 37718456
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract][Full Text] [Related]
25. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
Zhang L; Sun T; Sun B; Zhang K; Zheng Y; Li N; Chen L; Zheng C; Liang B; Shi H
BMC Cancer; 2024 Feb; 24(1):223. PubMed ID: 38365678
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Chen J; Zhou C; Long Y; Yin X
Tumour Biol; 2015 Jan; 36(1):183-91. PubMed ID: 25217986
[TBL] [Abstract][Full Text] [Related]
27. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
28. Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis.
Liu X; Li H; Wang F; Su K; He B; He J; Zhong J; Han Y; Li Z
BMC Gastroenterol; 2023 Sep; 23(1):299. PubMed ID: 37670232
[TBL] [Abstract][Full Text] [Related]
29. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation.
Zhou Q; An Y; Liu T; Liu Z; Li R; Wang C; Zhou F; Liu C; Zhu K
Int J Hyperthermia; 2022; 39(1):97-107. PubMed ID: 34979845
[TBL] [Abstract][Full Text] [Related]
30. Benefits of step-by-step debulking microwave ablation for huge unresectable hepatocellular carcinoma patients after transcatheter arterial chemoembolization refractoriness.
Huang T; Qi H; Shen L; Wu Y; Song Z; Cao F; Liu Y; Xie L; Chen S; Tang T; Li H; Zhang Y; Feng L; Zhang H; Chen J; Fan W
Int J Hyperthermia; 2022; 39(1):935-945. PubMed ID: 35853727
[TBL] [Abstract][Full Text] [Related]
31. Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy.
Qiao W; Wang Q; Hu C; Zhang Y; Li J; Sun Y; Yuan C; Wang W; Liu B; Zhang Y
Front Immunol; 2022; 13():1019772. PubMed ID: 36389724
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
Zhao S; Zhou M; Wang P; Yang J; Zhang D; Yin F; Song P
Technol Cancer Res Treat; 2022; 21():15330338221133640. PubMed ID: 36259214
[No Abstract] [Full Text] [Related]
33. Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study.
Duan X; Li H; Chen P; Sun T; Kuang D; Lu H; Qiao B; Fan Z; Ren Z; Han X
Eur Radiol; 2024 Feb; 34(2):1258-1267. PubMed ID: 37581654
[TBL] [Abstract][Full Text] [Related]
34. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.
Yin L; Liu KC; Lv WF; Lu D; Tan YL; Wang GX; Dai JY; Zhu XH; Jiang B
Cancer Imaging; 2023 May; 23(1):52. PubMed ID: 37254146
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
Yang XG; Sun YY; Li DS; Xu GH; Huang XQ
Front Immunol; 2022; 13():940009. PubMed ID: 35874708
[TBL] [Abstract][Full Text] [Related]
36. Safety evaluation of combination treatment of drug-eluting bead transarterial chemoembolization and immune checkpoint inhibitors for hepatocellular carcinoma: An increased risk of liver abscess with treatment interval less than one month.
Chiu SH; Lin HH; Feng AC; Lo CH; Hsieh CB; Chen PK; Chang WC
Eur J Radiol; 2024 Jan; 170():111266. PubMed ID: 38185027
[TBL] [Abstract][Full Text] [Related]
37. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
[TBL] [Abstract][Full Text] [Related]
38. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study.
Yuan Y; He W; Yang Z; Qiu J; Huang Z; Shi Y; Lin Z; Zheng Y; Chen M; Lau WY; Li B; Yuan Y
Int J Surg; 2023 May; 109(5):1222-1230. PubMed ID: 37026861
[TBL] [Abstract][Full Text] [Related]
39. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
[No Abstract] [Full Text] [Related]
40. Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study.
Yuan G; Li W; Zang M; Li R; Li Q; Hu X; Zhang Q; Huang W; Ruan J; Pang H; Chen J
Discov Oncol; 2024 Mar; 15(1):68. PubMed ID: 38460053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
